MA45154A - Procédés de préparation d'oligomères - Google Patents

Procédés de préparation d'oligomères

Info

Publication number
MA45154A
MA45154A MA045154A MA45154A MA45154A MA 45154 A MA45154 A MA 45154A MA 045154 A MA045154 A MA 045154A MA 45154 A MA45154 A MA 45154A MA 45154 A MA45154 A MA 45154A
Authority
MA
Morocco
Prior art keywords
preparation processes
oligomer preparation
oligomer
processes
preparation
Prior art date
Application number
MA045154A
Other languages
English (en)
Other versions
MA45154B1 (fr
Inventor
Richard K Bestwick
Bao Cai
Diane Elizabeth Frank
Mitchell Martini
Ross Shimabuku
Katie Thomas
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of MA45154A publication Critical patent/MA45154A/fr
Publication of MA45154B1 publication Critical patent/MA45154B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
MA45154A 2016-05-24 2017-05-24 Procédés de préparation d'oligomères MA45154B1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662341049P 2016-05-24 2016-05-24
US201662357166P 2016-06-30 2016-06-30
US201662357072P 2016-06-30 2016-06-30
US201662356923P 2016-06-30 2016-06-30
US201662357153P 2016-06-30 2016-06-30
US201762508256P 2017-05-18 2017-05-18
EP17731336.8A EP3464305B1 (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères
PCT/US2017/034235 WO2017205496A1 (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères

Publications (2)

Publication Number Publication Date
MA45154A true MA45154A (fr) 2019-04-10
MA45154B1 MA45154B1 (fr) 2024-11-29

Family

ID=59078165

Family Applications (2)

Application Number Title Priority Date Filing Date
MA45154A MA45154B1 (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères
MA049775A MA49775A (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères morpholino de phosphorodiamidate

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA049775A MA49775A (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères morpholino de phosphorodiamidate

Country Status (21)

Country Link
US (2) US10875880B2 (fr)
EP (2) EP3464305B1 (fr)
JP (2) JP7008642B2 (fr)
KR (1) KR102506298B1 (fr)
CN (1) CN109563114B (fr)
AU (1) AU2017269355B2 (fr)
BR (2) BR122022014984B1 (fr)
CA (1) CA3025339A1 (fr)
CO (1) CO2018013838A2 (fr)
DK (1) DK3464305T3 (fr)
ES (1) ES2993738T3 (fr)
FI (1) FI3464305T3 (fr)
HR (1) HRP20241428T1 (fr)
IL (1) IL263149B2 (fr)
MA (2) MA45154B1 (fr)
MD (1) MD3464305T2 (fr)
MX (2) MX2021008539A (fr)
SA (1) SA518400500B1 (fr)
SG (1) SG10202101830WA (fr)
TW (2) TWI801843B (fr)
WO (1) WO2017205496A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
SG10202101834QA (en) * 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
CN109563114B (zh) 2016-05-24 2022-08-12 萨勒普塔医疗公司 用于制备寡聚物的方法
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MX383656B (es) * 2016-05-24 2025-03-14 Sarepta Therapeutics Inc Procesos para preparar oligómeros de morfolino fosforodiamidato.
SG11201809497RA (en) 2016-05-24 2018-12-28 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
JP7022079B2 (ja) * 2016-06-30 2022-02-17 サレプタ セラピューティクス， インコーポレイテッド ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス
KR102523527B1 (ko) * 2016-06-30 2023-04-20 사렙타 쎄러퓨틱스 인코퍼레이티드 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법
TWI812647B (zh) * 2017-09-25 2023-08-21 美商薩羅塔治療公司 經由速流合成以製備磷醯二胺嗎啉代寡聚物之製程
EP3784248A4 (fr) * 2018-04-26 2022-08-10 Sarepta Therapeutics, Inc. Oligomères induisant le saut d'exon et conjugués d'oligomères pour la dystrophie musculaire
WO2024163762A2 (fr) * 2023-02-01 2024-08-08 Alnylam Pharmaceuticals, Inc. Cycle à six chaînons contenant des oligomères

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
AU5661386A (en) 1985-03-15 1986-10-13 Stirchak, E. Stereoregular polynucleotide-binding polymers
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
CA1339987C (fr) 1988-09-01 1998-08-04 Robert Bruce Merrifield Methode pour la synthese de peptides; support solide utile a cette fin
HUT76280A (en) 1993-12-29 1997-07-28 Fujisawa Pharmaceutical Co Pyrazolopyridine derivatives, pharmaceutical compositions containing them, process for proiducing them and their use
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
AU776362B2 (en) 1999-05-04 2004-09-09 Roche Innovation Center Copenhagen A/S L-ribo-LNA analogues
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
CA2459347C (fr) 2001-09-04 2012-10-09 Exiqon A/S Compositions d'acides nucleiques bloques et leurs utilisations
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
WO2004044140A2 (fr) 2002-11-05 2004-05-27 Isis Pharmaceticals, Inc. Composes oligomeres 2'-substitues et compositions destinees a etre utilisees dans des modulations genetiques
US7759513B2 (en) 2003-02-21 2010-07-20 Nigu Chemie Gmbh Photolabile protective groups for improved processes to prepare oligonucleotide arrays
SI2206781T1 (sl) 2004-06-28 2016-05-31 The University Of Western Australia Protismiselni oligonukleotidi za induciranje preskakovanja eksona in postopki njihove uporabe
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
ES2657400T3 (es) * 2006-05-10 2018-03-05 Sarepta Therapeutics, Inc. Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos
US9371348B2 (en) 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
CA2884340C (fr) * 2007-11-15 2017-07-25 Sarepta Therapeutics, Inc. Procede de synthese d'oligomeres morpholino
EP2762567B1 (fr) 2008-10-24 2016-07-13 Sarepta Therapeutics, Inc. Compositions de saut d'exon multiples pour dmd
CN102625840A (zh) 2009-04-10 2012-08-01 肌肉学研究协会 用于治疗疾病的三环dna反义寡核苷酸、组合物和方法
SMT201800579T1 (it) 2009-11-12 2019-01-11 Univ Western Australia Molecole antisenso e metodi per trattare patologie
TWI463423B (zh) * 2010-05-28 2014-12-01 Poynt Corp 用以針對基於三維形狀之廣告系統使用位置資訊的方法
JP2013530154A (ja) 2010-05-28 2013-07-25 サレプタ セラピューティクス， インコーポレイテッド 修飾されたサブユニット間結合および／または末端基を有するオリゴヌクレオチドアナログ
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
PL2623507T3 (pl) 2010-09-30 2017-03-31 Nippon Shinyaku Co., Ltd. Pochodna kwasu morfolinonukleinowego
EP2672977A1 (fr) * 2011-02-08 2013-12-18 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Oligonucléotides antisens
CN103889999B (zh) 2011-08-23 2021-06-01 皇家学习促进学会/麦吉尔大学 用于合成寡核糖核苷酸的离子标记
ES2535654T3 (es) 2011-10-13 2015-05-13 Association Institut De Myologie ADN triciclo-fosforotioato
BR112014011875B1 (pt) 2011-11-18 2022-01-04 Sarepta Therapeutics, Inc Oligonucleotídeos funcionalmente modificados e subunidades dos mesmos
AU2012345638C1 (en) * 2011-11-30 2018-10-18 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
CN108611349A (zh) * 2011-12-28 2018-10-02 日本新药株式会社 反义核酸
US9670529B2 (en) 2012-02-28 2017-06-06 Population Genetics Technologies Ltd. Method for attaching a counter sequence to a nucleic acid sample
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
KR20230074606A (ko) * 2013-03-14 2023-05-30 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이영양증의 치료를 위한 엑손 스키핑 조성물
AU2014236140B2 (en) * 2013-03-14 2019-10-03 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
NZ732507A (en) 2013-03-15 2018-08-31 Sarepta Therapeutics Inc Improved compositions for treating muscular dystrophy
CN105228999B (zh) * 2013-05-24 2021-03-02 味之素株式会社 吗啉代寡核苷酸的制备方法
SG11201809497RA (en) 2016-05-24 2018-12-28 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
CN109563114B (zh) 2016-05-24 2022-08-12 萨勒普塔医疗公司 用于制备寡聚物的方法
SG10202101834QA (en) 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MX383656B (es) * 2016-05-24 2025-03-14 Sarepta Therapeutics Inc Procesos para preparar oligómeros de morfolino fosforodiamidato.
KR102810425B1 (ko) 2016-12-19 2025-05-21 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
KR102646318B1 (ko) 2016-12-19 2024-03-12 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
HRP20240705T1 (hr) 2016-12-19 2024-08-30 Sarepta Therapeutics, Inc. Oligomerni konjugati koji preskaču egzon za mišićnu distrofiju
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии

Also Published As

Publication number Publication date
AU2017269355A1 (en) 2019-01-17
ES2993738T3 (en) 2025-01-08
BR122022014984B1 (pt) 2024-03-05
DK3464305T3 (da) 2024-10-28
AU2017269355B2 (en) 2021-04-15
TWI738784B (zh) 2021-09-11
JP2021176967A (ja) 2021-11-11
EP3464305A1 (fr) 2019-04-10
EP3564248A1 (fr) 2019-11-06
HRP20241428T1 (hr) 2025-01-03
TW202200599A (zh) 2022-01-01
TWI801843B (zh) 2023-05-11
KR20190015311A (ko) 2019-02-13
JP2019518832A (ja) 2019-07-04
MA49775A (fr) 2020-06-10
CN109563114A (zh) 2019-04-02
CA3025339A1 (fr) 2017-11-30
CN109563114B (zh) 2022-08-12
KR102506298B1 (ko) 2023-03-06
MX2021008539A (es) 2022-10-18
BR112018074346B1 (pt) 2023-01-03
WO2017205496A1 (fr) 2017-11-30
US20210198296A1 (en) 2021-07-01
MX384727B (es) 2025-03-14
IL263149B1 (en) 2023-01-01
JP7008642B2 (ja) 2022-01-25
CO2018013838A2 (es) 2019-01-18
IL263149B2 (en) 2023-05-01
SG10202101830WA (en) 2021-04-29
MD3464305T2 (ro) 2025-01-31
IL263149A (en) 2019-01-31
US10875880B2 (en) 2020-12-29
EP3464305B1 (fr) 2024-08-21
SA518400500B1 (ar) 2022-09-01
MA45154B1 (fr) 2024-11-29
US11384105B2 (en) 2022-07-12
MX2018014472A (es) 2019-05-23
US20200040020A1 (en) 2020-02-06
BR112018074346A2 (pt) 2019-03-06
FI3464305T3 (fi) 2024-10-30
TW201806962A (zh) 2018-03-01

Similar Documents

Publication Publication Date Title
MA45154A (fr) Procédés de préparation d'oligomères
EP3504196A4 (fr) Procédés de préparation d'olaparib
EP3706784A4 (fr) Compositions et procédés de production de lymphocytes t
MA45155A (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
EP3302575A4 (fr) Vecteurs d'édition de génome
EP3303413A4 (fr) Procédés de préparation de sugammadex et de ses intermédiaires
EP3353278A4 (fr) Préparation d'échantillons pour des types d'échantillons compliqués
EP3458531A4 (fr) Compositions de revêtement et leurs procédés de préparation
MA52906A (fr) Procédé de préparation d'amg 416
MA45183A (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
EP3423404A4 (fr) Nouvelles compositions de germanosilicates et procédés de préparation de celles-ci
EP3558312A4 (fr) Procédés d'amélioration de la densité vasculaire
EP3383783A4 (fr) Appareil d'alimentation à porte-à-faux équilibré
MA46717A (fr) Variantes de l'endonucléase homing tcra
EP2970037A4 (fr) Procédés de préparation d'alkylfurannes
EP3481200A4 (fr) Procédés de préparation de 4-alcoxy-3-(acyl ou alkyl)oxypicolinamides
MA42423A (fr) Procédé de préparation d'un revêtement
DK3679010T3 (da) Kulsyre-additionsprodukter
EP3500546A4 (fr) Propenylamines et leurs procédés de préparation et d'utilisation
EP3562798C0 (fr) Procédés d'oligomérisation d'éthylène
MA45362A (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
EP3390368A4 (fr) Procédés de préparation de 5,6-dihydro-6-phénylbenzo[f]isoquinoléine-2-amine substituée
EP3265100A4 (fr) Procédés de préparation de fluorokétolides
EP3317004A4 (fr) Appareil de préparation d'une solution, et procédés associés
MA46642A (fr) Promédicaments d'inhibiteurs de la kallicréine